Kezar Life Sciences (KZR) Fundamental Analysis: Revenue, Earnings & Valuation

2.61 / 10

Underperform

Fundamentally, KZR scores 2.6/10, marked underperform. Interest coverage and revenue‑to‑market are modest positives, yet high current‑liabilities ratio, negative PB‑ROE and asset‑to‑market drag performance. Overall fundamentals are weak and selective.

Analysis Checks(7/10)

Revenue-MV

Value-0.28

Score3/3

Weight45.53%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value78.03

Score2/3

Weight0.63%

1M Return0.13%

Inventory turnover ratio

Value47.95

Score2/3

Weight-5.19%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value90.68

Score1/3

Weight-7.26%

1M Return-1.69%

PB-ROE

Value-0.77

Score1/3

Weight36.79%

1M Return7.56%

Long-term debt to working capital ratio (%)

Value0.02

Score2/3

Weight-1.61%

1M Return-0.35%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-5.28%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value92.19

Score2/3

Weight0.25%

1M Return0.05%

Cost of sales ratio (%)

Value70.31

Score2/3

Weight-4.99%

1M Return-1.13%

Asset-MV

Value-0.49

Score1/3

Weight41.13%

1M Return6.31%

Is KZR fundamentally strong?

KZR scores 2.61/10 on fundamentals and holds a Premium valuation at present. Backed by its -59.93% ROE, 0.00% net margin, -0.97 P/E ratio, 0.78 P/B ratio, and 33.33% earnings growth, these metrics solidify its Underperform investment rating.